<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694459</url>
  </required_header>
  <id_info>
    <org_study_id>596-2012-D</org_study_id>
    <nct_id>NCT01694459</nct_id>
  </id_info>
  <brief_title>DEDICA (Dose of HEparin During Coronary Angioplasty) Trial</brief_title>
  <acronym>DEDICA</acronym>
  <official_title>Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Filippo Neri General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Filippo Neri General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International guidelines support the use of a full-dose heparin (anticoagulants) during&#xD;
      coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances&#xD;
      in angioplasty techniques and the widespread use of pretreatment with two antiplatelet&#xD;
      agents.&#xD;
&#xD;
      Thus the investigators designed a study comparing safety and efficacy of standard dose&#xD;
      heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty&#xD;
      who are on aspirin and clopidogrel at the time of the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients undergoing coronary angioplasty will be randomised to standard vs. low-dose&#xD;
           heparin. the study will include &quot;all-comers&quot; (patients with either stable angina or&#xD;
           acute coronary syndromes); only patients with ST-elevation myocardial infarction will be&#xD;
           excluded.&#xD;
&#xD;
        -  An ACT (activated clotting time) will be performed after the initial bolus of heparin:&#xD;
           for the standard dose group the target ACT will be &gt; 300 sec. (as recommended by&#xD;
           guidelines) while for the low-dose the target ACT will be &gt; 180 sec.&#xD;
&#xD;
      Aim of the study is to show equivalence in ischemic events between the two doses of heparin,&#xD;
      in order to confirm the safety of lower dose of heparin in contemporary coronary&#xD;
      interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE + stent thrombosis + major bleeding (TIMI definition)</measure>
    <time_frame>30 days</time_frame>
    <description>MACE (death, myocardial infarction, target vessel revascularization) + stent thrombosis + major bleeding (TIMI definition)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>30 days</time_frame>
    <description>MACE = death, myocardial infarction, target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding according to TIMI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>Stent thrombosis (definite or probable according to ARC criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CK-MB increase</measure>
    <time_frame>30 days</time_frame>
    <description>Any CK MB increase &gt;3 times upper limit of normal or &gt;50% baseline levels (if baseline levels already &gt;then upper limit of normal)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding according to STEEPLE criteria</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stable Angina</condition>
  <condition>Angina, Unstable</condition>
  <condition>Non-ST Elevation (NSTEMI) Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Standard dose heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) &gt; 300 sec. during the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus of 50 UI/Kg heparin with a target ACT during the procedure of &gt;200 sec.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose heparin</intervention_name>
    <description>Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions</description>
    <arm_group_label>Low-dose heparin</arm_group_label>
    <other_name>50 UI/Kg bolus heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose heparin</intervention_name>
    <description>Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.</description>
    <arm_group_label>Standard dose heparin</arm_group_label>
    <other_name>100 Ui/Kg bolus heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable angina, unstable angina or Non-ST elevation myocardial infarction undergoing&#xD;
             coronary angioplasty.&#xD;
&#xD;
          -  Mandatory pretreatment with aspirin and clopidogrel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ST elevation myocardial infarction&#xD;
&#xD;
          -  Coronary interventions with rotational atherectomy&#xD;
&#xD;
          -  Coronary interventions on chronic total occlusions (CTO)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Pasceri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Filippo Neri Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Pelliccia, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Roma La Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincenzo Pasceri, MD</last_name>
    <phone>+39063306</phone>
    <phone_ext>2504</phone_ext>
    <email>vpasceri@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+393483392006</phone>
    <email>md4151@mclink.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rome La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Pelliccia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Gaudio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 23, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Filippo Neri General Hospital</investigator_affiliation>
    <investigator_full_name>Vincenzo Pasceri</investigator_full_name>
    <investigator_title>Attending Cardiologist</investigator_title>
  </responsible_party>
  <keyword>angioplasty</keyword>
  <keyword>heparin</keyword>
  <keyword>trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

